Lixte Biotechnology Holdings, INC S-1 registration statements

Lixte Biotechnology Holdings, Inc. has completed two significant capital raises totaling $6.55 million to address its financial needs and Nasdaq listing compliance, while facing ongoing clinical trial hurdles and a 'going concern' warning from auditors.

Lixte Biotechnology Holdings, Inc. is undertaking a public offering of up to 7.69 million shares and pre-funded warrants to secure vital capital for operations and clinical trials, while simultaneously grappling with a Nasdaq compliance deadline and a significant clinical trial pause due to serious adverse events.

Lixte Biotechnology Holdings, a clinical-stage biopharmaceutical company, has filed an S-1 registration statement for a public offering of common stock and pre-funded warrants to raise capital, primarily to regain Nasdaq compliance and fund its operations, as it faces significant financial losses and challenges in its cancer therapy clinical trials.

Lixte Biotechnology Holdings files an amendment to its Form S-1 registration statement to correct a hyperlink and register shares for resale by selling stockholders upon exercise of warrants.

Lixte Biotechnology Holdings files an S-1 registration statement to allow selling stockholders to resell shares of common stock issuable upon exercise of warrants obtained in a recent financing.

Lixte Biotechnology Holdings is offering up to 1,895,734 units, each consisting of common stock or pre-funded warrants and common warrants, aiming to raise approximately $4 million for working capital and general corporate purposes, including advancing its cancer therapies.

Lixte Biotechnology Holdings is undertaking a best efforts offering of units, consisting of common stock or pre-funded warrants and common warrants, aiming to raise up to $4 million for working capital and general corporate purposes.

Lixte Biotechnology Holdings, Inc. is launching a reasonable best efforts offering of units to raise up to $[*] million for working capital and general corporate purposes.